PharmaPoint

Cobicistat (HIV)

Forecast and Market Analysis to 2022

GDHC1056DFR / Published January 2013

GlobalData

HIV: Key Metrics in the HIV Markets	
2022 Market Sales	
US	$23.8m
5EU	$2.8m
Total	**$26.7m**
Key Events (2012–2022)	**Level of Impact**
Launch of Cobicistat in the US in 2013	↑↑↑
Launch of Cobicistat in the 5EU in 2014	↑↑↑
Launch of Cobicistat in Japan in 2014	↑↑↑
Source: GlobalData	

Sales for Cobicistat by Region, 2022



Source: GlobalData

Sales for Cobicistat in the HIV Market

GlobalData expects Gilead to launch cobicistat in the US in 2013, and in the EU in 2014. We estimate that 2022 sales of cobicistat will reach $26.7 million across these markets.

Key factors affecting the uptake of cobicistat will include:

- Co-formulations of cobicistat with Janssen's Prezista and BMS's Reyataz are expected as soon as 2014
- The expiration of Norvir's patent in 2014 will result in cobicistat having to compete with generic pharmacokinetic (PK) boosters for patient share. This could prevent cobicistat from obtaining a premium price
- Single-pill, complete regimens, such Atripla and Complera, will challenge multi-pill regimens that would include cobicistat
- Probable switch of the majority of patients to single-tablet regimen (STRs)
- Market penetration of the new co-formulations is likely to be hindered in the forecast period due to avaialblity of lower-cost generics of Abbott's Norvir (ritonavir)

Key Opinion Leaders Interested in New and Efficacious Therapies that Improve the Treatment Algorithm for HIV Treatment

The Key Opinion Leaders (KOLs) interviewed for this report highlighted that the primary concerns for this market still remain disease awareness and patient compliance with existing treatment regimens. They also embrace the adoption of aggressive efforts to diagnose new infections and start people on antiretrovirals. In terms of treatment choice, these KOLs indicated that integrase inhibitor-based regimens are likely to be the wave of the future of the market due to the emergence of viral resistance through the use of other treatments. KOLs also show a preference to simplified regimens and fixed dose combinations and would like to see more treatment choices as STRs.

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

"The most of what I would like to see is not related to drug so much as it is to the healthcare system, getting more people diagnosed and retained in care."

Key Opinion Leader, January 2013

"The major hurdles which prevent patients from getting diagnosed are lack of awareness on the part of physicians [they should be testing] and lack of access to healthcare for many patients."

Key Opinion Leader, January 2013

"Yes, we do perform screening for all high-risk patients. General hospitals also perform routine screening for all patients who are admitted. So, 70% to 80% of the new HIV-positive patients come from general hospitals. More and more patients are tested for HIV and they are forced into diagnosis."

Key Opinion Leader, November 2012

"We have the test-and-treat policy. If we identify a positive patient we immediately start therapy, and it helps preventing opportunistic infections and malignancies."

Key Opinion Leader, November 2012

"When you talk to patients they are quite keen on injectable drugs once a month."

Key Opinion Leader, November 2012

"My personal advice to the companies would be to conduct many more studies with people who are likely to be less adherent; poorly adherent patients, patients with high viral loads and low CD4+ counts."

Key Opinion Leader, November 2012

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
3.2.1 Primary or Acute Infection 16
3.2.2 Chronic Infection 16
3.2.3 Advanced Infection/AIDS 17
4 Disease Management 18
4.1 Treatment Overview 18
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 22
6 Opportunity and Unmet Need 25
6.1 Overview 25
6.1.1 Simplified regimens and dosing frequency 25
6.1.2 Side effects and toxicities 26
6.1.3 Drug resistance 26

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

6.1.4 Prophylaxis 27
6.1.5 Lack of functional cure 27
6.1.6 Patient awareness 28
6.1.7 Treatment availability 28
6.1.8 Treatment affordability 29
6.2 Unmet Needs Gap Analysis 29
6.3 Opportunities 31
6.3.1 Development of treatments to counter drug resistance 31
6.3.2 Collaborations to develop newer STRs 31
6.3.3 Development of new injectable formulations 31
6.3.4 Development of new prophylactics 32
6.3.5 Development of drugs that use a novel mechanism of action 32
6.3.6 Public-Private Partnerships 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 34
8 Cobicistat 37
8.1 Overview 37
8.2 Efficacy 39
8.3 Safety 40
8.4 Dosing and Formulation 40
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 41
8.7 Pricing and Reimbursement 41
8.8 SWOT Analysis 42
8.9 Forecast 43
9 Appendix 45
9.1 Bibliography 45

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

9.2 Abbreviations 49
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 HIV Prevalence 51
9.4.2 Percent Drug-Treated Patients 51
9.4.3 General Pricing Assumptions 52
9.4.4 Generic Erosion 53
9.4.5 Pricing of Pipeline agents 53
9.5 Physicians and Specialists Included in this Study 54
9.5.1 Survery of Prescribing Physicians 55
9.6 About the Authors 56
9.6.1 Authors 56
9.6.2 Global Head of Healthcare 57
9.7 About GlobalData 58
9.8 Contact Us 58
9.9 Disclaimer 58

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

1.1 List of Tables

Table 1: Symptoms HIV....17
Table 2: Treatment Guidelines for HIV....19
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012....20
Table 4: Leading Treatments for HIV, 2012....24
Table 5: Overall Unmet Needs – Current Level of Attainment....25
Table 6: Clinical Unmet Needs – Gap Analysis, 2012....30
Table 7: HIV – Promising Drugs in Clinical Development, 2012....34
Table 8: Comparison of Therapeutic Classes in Development for HIV, 2012....36
Table 9: Product Profile – Cobicistat....39
Table 10: Cobicistat SWOT Analysis, 2012....43
Table 11: Global Sales Forecasts ($m) for cobicistat, 2012–2022....44
Table 12: Physicians Surveyed, By Country....55

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

1.2 List of Figures

Figure 1: HIV Lifecycle.....13

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2012–2022.....35

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

2 Introduction

2.1 Catalyst

Globaldata expects cobicistat to reach 26.7 million by 2022 with intense corporate competition between pharmaceutical giants.

- The decrease in the CD4 count threshold required of asymptomatic patients prior to the administration of antiretroviral therapy, and the test-and-treat approach adopted by many countries, is likely to increase the market size.
- The 2012 approval of Gilead's new single-tablet regimen (STR), Stribild, introduces a new fixed-dose combinatorial drug onto the market and underscores the patient and physician preference for STRs for HIV treatment.
- Gilead's "cash-cow", Truvada, received approval as the first-ever treatment to be used as a pre-exposure prophylactic treatment in HIV-negative patients who are in high risk of exposure to HIV infection.
- The movement towards compulsory licensing in emerging markets, such as Brazil and China, in favor of providing affordable treatments to infected individuals, has a ripple effect on the size of these markets and the attractiveness of the market as a whole.
- The impending patent expiries of high-grossing drugs, such as BMS's Sustiva (a component of Atripla), Gilead's Atripla and Truvada, ViiV's Epzicom, and AbbVie's Norvir and Kaletra are expected to dramatically change the face of the market in favor of generic drugs and pushing manufacturers to develop more efficacious products in order to retain their market share in the long term.

2.2 Related Reports

- GlobalData (2013). HIV – United States Drug Forecast and Market Analysis to 2022. GDHC1029CFR
- GlobalData (2013). HIV– United Kingdom Drug Forecast and Market Analysis to 2022. GDHC1034CFR
- GlobalData (2013). HIV – France Drug Forecast and Market Analysis to 2022. GDHC1030CFR
- GlobalData (2013). HIV – Germany Drug Forecast and Market Analysis to 2022. GDHC1031CFR

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

- GlobalData (2013). HIV – Italy Drug Forecast and Market Analysis to 2022. GDHC1032CFR
- GlobalData (2013). HIV – Spain Drug Forecast and Market Analysis to 2022. GDHC1033CFR
- GlobalData (2013). HIV – Japan Drug Forecast and Market Analysis to 2022. GDHC1035CFR
- GlobalData (2013). HIV – China Drug Forecast and Market Analysis to 2022. GDHC1037CFR
- GlobalData (2013). HIV – Brazil Drug Forecast and Market Analysis to 2022. GDHC1036CFR
- GlobalData (2013). Atripla (HIV) – Forecast and Market Analysis to 2022. GDHC1116DFR
- GlobalData (2013).Complera (HIV) – Forecast and Market Analysis to 2022. GDHC1115DFR
- GlobalData (2013). Stribild (HIV) – Forecast and Market Analysis to 2022. GDHC1114DFR
- GlobalData (2013).Truvada(HIV) – Forecast and Market Analysis to 2022. GDHC1112DFR
- GlobalData (2013).Epzicom(HIV) – Forecast and Market Analysis to 2022. GDHC1113DFR
- GlobalData (2013).Kaletra (HIV) – Forecast and Market Analysis to 2022. GDHC1051DFR
- GlobalData (2013).Reyataz(HIV) – Forecast and Market Analysis to 2022. GDHC1052DFR
- GlobalData (2013).Prezista(HIV) – Forecast and Market Analysis to 2022. GDHC1053DFR
- GlobalData (2013). Norvir (HIV) – Forecast and Market Analysis to 2022. GDHC1054DFR
- GlobalData (2013).Isentress(HIV) – Forecast and Market Analysis to 2022. GDHC1055DFR
- GlobalData (2013). Dolutegravir(HIV) – Forecast and Market Analysis to 2022. GDHC1058DFR
- GlobalData (2013). 572-Trii (HIV) – Forecast and Market Analysis to 2022. GDHC1059DFR
- GlobalData (2013). Quad 2 (HIV) – Forecast and Market Analysis to 2022. GDHC1060DFR
- GlobalData(2013).Elvitegravir(HIV) – Forecast and Market Analysis to 2022. GDHC1057DFR
- GlobalData (2013). HIV – Current and Future Players. GDHC1004FPR

SAMPLE

© GlobalData.
This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

9.7 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, Boston, London, India, and Singapore.

9.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

SAMPLE